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OBJECTIVES The purpose of this study was to compare early and late clinical outcomes in diabetic and
nondiabetic patients after stent implantation in saphenous vein grafts (SVG).
BACKGROUND Patients with diabetes mellitus have less favorable acute and long-term outcomes after stent
implantation in native coronary arteries. The impact of diabetes on SVG stenting, however,
is not known.
METHODS We studied 908 consecutive patients (1,366 SVG lesions) treated with Palmaz-Schatz stents.
In-hospital and late clinical outcomes (death, Q-wave myocardial infarction and repeat
revascularization rates at one year) were compared between diabetic (n 5 290) and
nondiabetic (n 5 618) patients.
RESULTS In-hospital mortality was significantly higher in diabetic as compared with nondiabetic
patients (2.2% vs. 0.3%, p 5 0.003). At one-year follow-up, target lesion revascularization
(TLR) was 16.6% in diabetic and 12.3% in nondiabetic patients (p 5 0.03). Overall cardiac
event-free survival (freedom from death, Q-wave myocardial infarction and any coronary
revascularization procedure) at one year was significantly lower in the diabetic (68%)
compared with the nondiabetic patients (79%, p 5 0.0003). By Cox regression analysis,
diabetes mellitus was an independent predictor of both TLR (relative risk: 1.23; confidence
interval: 0.96 to 1.58; p 5 0.004) and late cardiac events (relative risk: 1.40; confidence
interval: 1.05 to 1.86; p 5 0.02).
CONCLUSIONS Patients with diabetes undergoing stent implantation in SVG have: 1) higher in-hospital and
late mortality, 2) higher one-year TLR rates, and 3) significantly lower one-year cardiac
event-free survival. Thus, diabetic patients have less favorable acute and late clinical outcomes
after stent implantation in SVG lesions. (J Am Coll Cardiol 2000;36:1186–93) © 2000 by
the American College of Cardiology
Patients with diabetes mellitus are at increased risk of
restenosis after balloon angioplasty resulting in increased
late morbidity and mortality compared with nondiabetic
patients (1–3). Two large randomized trials have shown that
coronary stents improve procedural outcome and reduce
restenosis in focal de novo native coronary artery lesions
compared with balloon angioplasty (4,5). Although stents
may improve results compared with balloon angioplasty in
diabetic patients (6), these patients still have increased
incidence of complications and in-stent restenosis compared
with nondiabetic patients (7–9). Despite the fact that several
studies have examined the impact of diabetes mellitus on
short and long-term clinical outcomes after stent implanta-
tion in native coronary arteries (7–9), little is known about
the influence of diabetes after stent implantation in saphe-
nous vein grafts (SVGs).
In order to evaluate the impact of diabetes on the acute
and late clinical outcomes in a consecutive series of patients
undergoing stent implantation in SVG, we compared in-
hospital and one-year clinical outcomes among nondiabetic
and diabetic patients, and within the diabetic group, be-
tween patients requiring insulin therapy or oral hypoglyce-
mic agents.
METHODS
Study population. The patient cohort included a consec-
utive series of 908 patients (1,366 SVG lesions) in the
Cardiovascular Research Foundation Angioplasty Database
treated with Palmaz-Schatz stents (Johnson and Johnson
Interventional Systems, Warren, New Jersey) between
March 1994 and September 1997. All patients gave written
informed consent approved by the Institutional Review
Board of the Washington Hospital Center before the
procedure. Patients were divided into three groups accord-
ing to their diabetic status. There were 618 (68.1%) patients
without diabetes, 189 (20.8%) diabetic patients treated with
oral hypoglycemic agents and 101 (11.1%) diabetic patients
requiring insulin therapy. Patients were classified as diabetic
From the *Washington Hospital Center, Washington, DC; †Cornell University—
New York Presbyterian Hospital, New York, New York; and the ‡Cardiovascular
Research Foundation, New York, New York. Supported, in part, by the Cardiovas-
cular Research Foundation.
Manuscript received October 18, 1999; revised manuscript received March 27,
2000, accepted June 1, 2000.
Journal of the American College of Cardiology Vol. 36, No. 4, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00861-5
if they required insulin or oral hypoglycemic treatment at
the time of initial interventional procedure.
Baseline clinical demographics and in-hospital events
were confirmed by independent chart review. Clinical out-
comes at one year were obtained by serial telephone inter-
views at one, three, six and 12 months by research nurses.
Any late clinical events (death, Q-wave myocardial infarc-
tion [MI], target lesion revascularization [TLR], any angio-
plasty or bypass surgery [CABG]) were adjudicated and
corroborated by accompanying source documentation by a
dedicated data coordinating center. In addition to TLR,
target vessel revascularization rate is also reported.
Stent types and deployment techniques. The types of
stents used were either coronary (n 5 574, 33.6%) or
“biliary” (n 5 1,132, 66.4%) tubular slotted stents (Palmaz-
Schatz type). Coronary stents were used for vessels ,4 mm
in diameter, and the larger biliary type stents were reserved
for vessels .4 mm in diameter. Details of the stent design
and implantation technique have been previously described
(4,5). Optimal stent implantation was carefully monitored
using an interactive technique with on-line intravascular
ultrasound (IVUS) interpretation in .90% of the cases.
Atheroablation was performed in 361 (26.4%) lesions before
stent implantation. All patients received 325 mg of aspirin
before the procedure and continued indefinitely. After the
stent placement, Ticlopidine (250 mg twice daily) was given
to all patients for four weeks. Glycoprotein IIb/IIIa inhib-
itors were used in ,3% of the patients in all treatment
groups.
Angiographic and IVUS analysis. Angiographic analysis
was performed using a validated, automated edge-detection
algorithm (CMS, MEDIS, Leiden, the Netherlands) as
previously described (10).
Intravascular ultrasound studies were performed after
intragraft injection of 200 mg of nitroglycerin with a
commercially available scanner (Boston Scientific Corpora-
tion/Cardiovascular Imaging System, Maple Grove, Min-
nesota).
The Core Laboratory at the Washington Hospital Center
analyzed the IVUS studies. Using computer planimetry
(TapeMeasure, Indec System, Mountain View, California),
lesion site and reference segment external elastic membrane
(EEM) cross-sectional area (CSA), lumen CSA and plaque
plus media were measured according to the validated pro-
tocols (11–13).
Statistical analysis. Statistical analysis was performed us-
ing StatView 4.5 or SAS (SAS Institute, Cary, North
Carolina). Continuous variables are presented as mean 6 1
standard deviation and were compared using unpaired t test.
Categorical variables are presented as percent frequencies,
and comparison between groups was performed using chi-
square test. Stepwise regression analysis was used to deter-
mine whether diabetes was an independent predictor of
in-hospital mortality. Cox proportional hazard regression
analysis (14) was used to assess the relative risk of diabetes
and other clinical, morphological and procedural variables
on death, TLR and other adverse cardiac events at one-year
follow-up. First, univariate logistic regression analysis was
performed, and then variables with a p value of ,0.2 were
entered into the Cox model. These variables included age,
gender, presence of diabetes, hypertension, previous history
of MI, graft age, restenotic lesions, ostial lesion location,
lesion length, prestent atheroablation, type of stents, pre-
procedural and final reference diameter, minimal lumen
diameter before and after intervention and final lesion CSA
by IVUS.
Cumulative event-free survival curves were calculated and
displayed using the SAS LIFE test analysis. The Wilcoxon
log rank test was used for survival comparison between
groups (diabetic vs. nondiabetic patients and diabetic pa-
tients requiring insulin vs. oral hypoglycemic treatment).
Values of p ,0.05 were accepted as significant.
Abbreviations and Acronyms
CABG 5 coronary artery bypass surgery
CI 5 confidence interval
CSA 5 cross-sectional area
EEM 5 external elastic membrane
IVUS 5 intravascular ultrasound
MI 5 myocardial infarction
RR 5 relative risk
SVG 5 saphenous vein graft
TLR 5 target lesion revascularization
Table 1. Baseline Characteristics of the Study Population
Patients
Nondiabetics
(n 5 618)
All Diabetics
(n 5 290) p Value
IRDM
(n 5 101)
NIRDM
(n 5 189) p Value
Age (yr) 67 6 9 67 6 8 0.81 66 6 9 67 6 8 0.49
Male gender (%) 84.4 71.6 0.001 63.4 75.7 0.02
Unstable angina (%) 75.9 79.2 0.25 82.0 77.7 0.36
Hypertension (%) 60.6 75.2 0.001 78.6 73.3 0.29
Hypercholesterolemia (%) 69.4 71.7 0.45 68.8 73.3 0.38
Prior infarction (%) 63.8 63.4 0.91 62.3 64.0 0.76
Prior angioplasty (%) 42.7 42.2 0.19 51.8 44.7 0.22
LVEF (mean 6 SD) 0.41 6 0.13 0.41 6 0.14 0.97 0.40 6 0.12 0.41 6 0.14 0.14
Graft age (months) 110 6 54 90 6 54 0.001 87 6 59 92 6 51 0.41
IRDM 5 insulin-requiring diabetics; LVEF 5 left ventricular ejection fraction; NIRDM 5 noninsulin-requiring diabetics; SD 5 standard deviation.
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RESULTS
Baseline demographics. Baseline characteristics of all
treated patients are shown in Table 1. Patients with diabetes
were more often women and had a higher prevalence of
hypertension. Patients without diabetes had significantly
older graft age in comparison with patients with diabetes.
Procedural and angiographic characteristics. Procedural
and angiographic characteristics are shown in Tables 2 and
3. A total of 1,679 stents were deployed in 908 patients with
1,366 lesions. The mean number of stents per lesion was
1.23 6 0.55 and per vessel was 1.79 6 1.07. In 1,105
(80.8%) lesions a single stent was used, and two stents were
used in 219 (16.0%) lesions. Three stents were implanted in
42 (3.0%) lesions. Average balloon size was 4.25 6 0.70,
and mean final inflation pressure was 14 6 4. The average
balloon-to-artery ratio used for final stent expansion was
1.29 6 0.25.
Patients with diabetes requiring insulin treatment had
Table 2. Qualitative and Quantitative Angiographic Analysis
Lesions
Nondiabetics
(n 5 933)
All Diabetics
(n 5 433) p Value
IRDM
(n 5 152)
NIRDM
(n 5 281) p Value
Lesion location (%)
Ostial 20.9 22.6 0.81 22.7 22.5 0.97
Proximal 29.4 31.8 0.3 38.2 27.4 0.03
Mid 28.3 26.9 0.3 27.4 26.6 0.87
Distal 20.6 17.9 0.7 11.5 22.3 0.01
Lesion characteristics (%)
Total occlusion 3.7 3.9 0.93 5.9 3.1 0.29
Restenosis 23.3 24.0 0.76 19.1 26.8 0.07
Eccentric lesions 58.9 55.6 0.37 57.4 55.0 0.74
Thrombus 14.7 7.47 0.03 7.4 7.4 0.99
SVG degeneration 39.1 38.2 0.81 56.5 32.1 0.001
Ulceration 20.2 20.1 0.95 17.6 20.9 0.56
Lesion length $10 mm 34.8 32.5 0.52 31.3 33.0 0.80
Lesion length $20 mm 8.4 8.7 0.89 14.9 6.5 0.03
Lesion length (mm) 10.0 6 7.6 9.8 6 8.2 0.82 10.8 6 10.5 9.5 6 7.2 0.35
Lesion class B2 or C 68.9 66.4 0.26 75.0 63.3 0.001
Procedural complications (%)
Procedural dissection 5.0 4.4 0.75 2.6 6.0 0.14
Abrupt closure 0.5 0.0 0.55 0.0 0.0
Aneurysm 7.7 5.6 0.43 7.4 4.1 0.48
No reflow 1.4 2.8 0.45 4.4 1.3 0.34
Perforation 0.7 0.4 0.60 1.4 0.0 0.26
Distal embolization 2.7 2.6 0.90 2.9 2.7 0.97
Quantitative measurements
Proximal reference, mm 3.4 6 0.7 3.3 6 0.6 0.67 3.4 6 0.6 3.3 6 0.6 0.35
Lesion MLD, mm
Preprocedure 1.1 6 0.6 1.1 6 0.6 0.61 1.0 6 0.6 1.1 6 0.6 0.73
Postprocedure 3.2 6 0.6 3.1 6 0.6 0.08 3.2 6 0.6 3.0 6 0.6 0.05
Lesion % diameter stenosis
Preprocedure 66.8 6 17.6 66.7 6 17.7 0.93 67.5 6 17.4 66.3 6 17.8 0.63
Postprocedure (final) 6.1 6 16.0 7.5 6 15.1 0.26 5.2 6 17.8 8.3 6 13.9 0.18
DS 5 diameter stenosis; IRDM 5 insulin-requiring diabetics; MLD 5 minimum lumen diameter; NIRDM 5 noninsulin-requiring diabetics; SVG 5 saphenous vein graft.
Table 3. Procedural Characteristics
Lesions
Nondiabetics
(n 5 933)
All Diabetics
(n 5 433) p Value
IRDM
(n 5 152)
NIRDM
(n 5 281) p Value
Stent types
Palmaz-Schatz (%) 37.9 44.6 0.06 51.4 39.6 0.01
Biliary (%) 62.1 55.4 0.02 48.7 60.1 0.03
Stent/lesion 1.22 6 0.5 1.27 6 0.6 0.55 1.34 6 0.7 1.23 6 0.5 0.10
Stent/vessel 1.77 6 1.0 1.87 6 1.1 0.23 1.87 6 1.0 1.77 6 1.1 0.12
Final balloon size 4.30 6 0.7 4.13 6 0.7 0.001 4.10 6 0.7 4.14 6 0.6 0.66
Balloon/artery ratio 1.30 6 0.2 1.28 6 0.2 0.86 1.26 6 0.2 1.31 6 0.2 0.23
Maximum pressure (atm) 13.3 6 3.8 14.1 6 4.6 0.04 14.2 6 4.7 14.0 6 4.5 0.79
Interventional procedure (%)
Excimer laser 19.3 19.2 0.95 25.0 16.0 0.02
Directional atherectomy 4.3 3.5 0.04 2.0 4.3 0.21
Extractional atherectomy 5.3 2.1 0.007 2.0 2.1 0.98
IRDM 5 insulin-requiring diabetics; NIRDM 5 noninsulin-requiring diabetics.
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more degenerated SVG compared with noninsulin-
requiring diabetic patients or nondiabetic patients. Throm-
bus containing lesions were more common in nondiabetic as
compared with diabetic patients. The incidence of postpro-
cedural angiographic complications, such as distal emboli-
zation, thrombus and no reflow, was similar between dia-
betic and nondiabetic patients and within the diabetic
group.
By quantitative coronary angiography, preprocedural and
postprocedure measurements were similar for both nondia-
betic and diabetic patients except for postintervention min-
imum lumen diameter, which was larger in diabetic patients
requiring insulin treatment (3.2 6 0.67 mm) compared with
diabetic patients treated with oral hypoglycemic agents
(3.0 6 0.63 mm; p 5 0.05), with no difference between
diabetic and nondiabetic patients.
IVUS results. Preintervention IVUS measurements were
similar between diabetic and nondiabetic patients except for
EEM CSA at the reference and lesion sites, which were
significantly smaller in diabetic patients (Table 4). After
intervention, only the lesion site EEM CSA was signifi-
cantly smaller in diabetic as compared with nondiabetic
patients. There were no significant differences between
diabetic patients requiring insulin or oral hypoglycemic
treatment.
In-hospital results. Overall procedural success was uni-
formly high in all groups (Table 5). However, combined
major in-hospital complications (death, Q-wave MI and
emergent CABG) were more frequent in diabetic as com-
pared with nondiabetic patients (4.7% vs. 2.2%; p 5 0.02),
with no difference between diabetic patients requiring insu-
lin or oral hypoglycemic treatment (p 5 0.69). In-hospital
Table 4. Intravascular Ultrasound Analysis
Lesions
Nondiabetics
(n 5 933)
All Diabetics
(n 5 433) p Value
IRDM
(n 5 152)
NIRDM
(n 5 281) p Value
Preintervention
Reference
Lumen CSA (mm2) 12.4 6 3.4 11.6 6 5.6 0.21 11.5 6 3.0 11.3 6 3.5 0.69
EEM CSA (mm2) 19.9 6 8.9 17.4 6 5.7 0.01 17.0 6 5.2 17.7 6 6.0 0.63
P1M CSA (mm2) 8.2 6 4.7 7.4 6 4.4 0.19 7.8 6 5.6 7.1 6 3.6 0.57
Lesion
Lumen CSA (mm2) 2.9 6 1.7 2.7 6 1.5 0.28 2.7 6 1.5 2.7 6 1.5 0.88
EEM CSA (mm2) 20.6 6 8.5 18.3 6 9.6 0.05 16.6 6 6.0 19.4 6 11.0 0.11
MLD (mm) 1.6 6 0.4 1.6 6 0.4 0.21 1.54 6 0.4 1.6 6 0.4 0.24
P1M CSA (mm2) 17.7 6 8.2 15.7 6 9.1 0.08 13.9 6 5.4 16.8 6 10.6 0.10
CSN % 84.7 6 9.6 83.9 6 9.3 0.55 83.7 6 9.0 84.1 6 9.5 0.86
Postintervention
Lesion
Lumen CSA (mm2) 10.1 6 3.7 9.8 6 5.9 0.66 10.4 6 8.4 9.5 6 3.5 0.50
MLD (mm) 3.1 6 0.5 3.0 6 0.5 0.48 3.1 6 0.5 3.0 6 0.6 0.60
EEM CSA (mm2) 26.8 6 9.7 23.0 6 9.2 0.003 20.6 6 8.6 24.3 6 9.4 0.08
CSN % 62.4 6 19.4 58.3 6 16.0 0.10 55.1 6 13.2 60.2 6 17.2 0.18
CSA 5 cross-sectional area; CSN 5 cross-sectional narrowing; EEM 5 external elastic membrane; IRDM 5 insulin-requiring diabetics; MLD 5 mininum luminal diameter;
NIRDM 5 noninsulin-requiring diabetics; P1M 5 plaque plus media.
Table 5. Clinical Events
Patients
Nondiabetics
(n 5 618)
All Diabetics
(n 5 290) p Value
IRDM
(n 5 101)
NIRDM
(n 5 189) p Value
In-hospital (%)
Procedural success 97.8 95.2 0.15 94.6 95.5 0.49
Overall major complications 2.2 4.7 0.02 4.9 4.4 0.69
Death 0.3 2.2 0.003 2.0 2.4 0.92
Q-wave infarction 1.2 1.3 1.0 1.8 1.0 0.61
CABG 0.6 1.3 0.21 1.8 1.0 0.61
Repeat angioplasty 1.2 1.6 0.56 2.7 1.0 0.34
Subacute thrombosis 1.6 1.2 1.0 1.5 1.1 0.97
Non-Q-wave infarction 17.8 15.2 0.32 13.6 16.1 0.57
One-year follow-up (%)
Death 5.0 12.3 0.001 13.4 11.7 0.65
Q-wave infarction 1.8 2.5 0.26 3.6 1.9 0.61
TLR-angioplasty 9.6 13.6 0.02 18.6 17.8 0.85
TLR-CABG 2.9 3.2 0.73 4.1 4.3 0.87
Overall TLR 16.6 12.3 0.03 3.3 3.2 0.98
TVR 22.6 17.2 0.04 23.1 21.4 0.57
Cardiac event-free survival 79 67 0.0003 69 66 0.31
CABG 5 coronary artery bypass surgery; IRDM 5 insulin-requiring diabetics; NIRDM 5 noninsulin-requiring diabetics; TLR 5 target lesion revascularization; TVR 5 target
vessel revascularization.
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mortality was significantly higher in the diabetic as com-
pared with the nondiabetic patients (2.2% vs. 0.3,
p 5 0.003). On subgroup analysis there was no difference in
mortality between the two diabetic populations (1.8% vs.
2.4%; p 5 0.98). By multivariate regression analysis, pres-
ence of diabetes was found to be the only predictor of
in-hospital mortality (odds ratio: 4.79; confidence interval
[CI]: 1.65 to 13.9; p 5 0.004). The prevalence of peripro-
cedural non-Q-wave MI (creatine kinase isoenzyme $5
times normal) was similar in diabetic and nondiabetic
patients (18% vs. 15%; p 5 0.35), as was the incidence of
subacute stent thrombosis (1.2% vs. 1.6%; p 5 0.99).
Late clinical outcomes. Clinical follow-up at one year was
available in 280 of 290 (96.5%) diabetic patients and 606 of
618 (98.0%) nondiabetic patients (Table 5), with identifi-
cation of clinical events that could be objectively substanti-
ated (death, Q-wave MI and repeat revascularization). At
one year overall TLR was significantly higher in diabetic
patients (16.6% vs. 12.3%, p 5 0.03), as was the rate of any
target vessel revascularization (22.6% vs. 17.2%, p 5 0.04).
Similarly, the overall cardiac event rate (death, Q-wave MI,
TLR and any revascularization) was also higher in diabetic
compared with nondiabetic patients (32.9% vs. 21.5%, p 5
0.001). Patients with diabetes more often underwent repeat
angioplasty (13.6% vs. 9.6%, p 5 0.02) than patients
without diabetes. The cumulative death rate at one year was
12.3% for diabetic and 5% for nondiabetic patients (p 5
0.001). Cardiac event-free survival (freedom from death,
Q-wave MI, angioplasty or CABG) at one year was 68% in
diabetic patients, significantly lower compared with 79% in
nondiabetic patients (p 5 0.0003), with no subgroup
difference between the two diabetic populations (64% vs.
65%, p 5 0.31). Actuarial cardiac event-free survival curves
for any cardiac event and for TLR between diabetic and
nondiabetic patients and between diabetic patients requiring
insulin or oral hypoglycemic treatment are shown in Figures
1 and 2, respectively.
Cox regression analysis was used to identify the indepen-
dent predictors of any major adverse cardiac events (death,
Q-wave MI, angioplasty or CABG) and TLR at one-year
follow-up. Independent predictors of TLR were presence of
diabetes (relative risk [RR]: 1.23; CI: 0.96 to 1.58; p 5
Figure 1. Actuarial event-free survival curves for any adverse cardiac events (death, Q-wave infarction, angioplasty and coronary artery bypass surgery, top)
and TLR (bottom) for 12 months after stenting in diabetic versus nondiabetic patients. TLR 5 target lesion revascularization.
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0.004) and prestent atheroablation (RR: 1.85; CI: 1.31 to
2.60; p 5 0.0004). Hypertension (RR: 1.47; CI: 1.10 to
1.98; p 5 0.009), presence of diabetes (RR: 1.40; CI: 1.05
to 1.86; p 5 0.02), history of MI (RR: 1.38; CI: 1.04 to
1.84; p 5 0.02), final reference diameter (RR: 0.62; CI: 0.40
to 0.99; p 5 0.04) and prestent atheroablation (RR: 1.52;
CI: 1.01 to 2.30; p 5 0.04) were found to predict late
cardiac events at one year.
DISCUSSION
This study shows that diabetic patients compared with
nondiabetic patients undergoing stent implantation in SVG
have: 1) higher in-hospital and late mortality, 2) higher
one-year target lesion revascularization rates, and 3) signif-
icantly lower one-year cardiac event-free survival. In this
study we also found that the presence of diabetes and
prestent atheroablation are the independent predictors of
clinical restenosis, whereas hypertension, presence of diabe-
tes, history of MI, final reference diameter and prestent
atheroablation are predictive for composite cardiac events.
Treatment of SVG disease. Balloon angioplasty of SVG
has been limited by frequent periprocedural complications
and high incidence of late restenosis (15,16). Repeat CABG
is associated with increased morbidity and mortality and
provides less symptomatic relief as compared with initial
operation (17,18). Several studies have reported favorable
results of stent implantation in the SVG lesions (19–22). In
the large multicenter U.S. Palmaz-Schatz stent series in
SVG lesions, Wong et al. (20) demonstrated that stent
implantation in patients with focal SVG lesions is associated
with high deployment and procedural success, excellent
angiographic results, acceptable complications, six months
angiographic restenosis of 29.7% and favorable late clinical
outcome. Likewise, in a randomized comparison of stents
and balloon angioplasty Savage et al. (23) have demon-
strated angiographic success in 97% of the patients in the
stent group and 86% of the patients in the balloon group
Figure 2. Actuarial event-free survival curves for any adverse cardiac events (death, Q-wave infarction, angioplasty and coronary artery bypass surgery, top)
and TLR (bottom) for 12 months after stenting in patients with insulin-requiring diabetes versus noninsulin-requiring diabetes (on oral hypoglycemic
agents). IRDM 5 insulin-requiring diabetics; NIRDM 5 noninsulin-requiring diabetics; TLR 5 target lesion revascularization.
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(p , 0.001). Restenosis occurred in 46% of the patients
assigned to balloon angioplasty and in 37% of the patients in
the stent group. In our study procedural success was
achieved in over 97% of the patients, which is similar to
above studies. The overall (including both diabetic and
nondiabetic patients) event-free survival in this study (73%)
is also comparable to the above studies (76.3% and 73%,
respectively). However, in studies by Wong et al. (20) and
Savage et al. (23), patients with only focal lesions were
treated with stent implantation, whereas in this study both
focal and diffuse lesions were included. Unlike previous
reports, the clinical restenosis rate in this study was signif-
icantly lower. This lower rate may be related to improved
stent techniques, use of IVUS guidance or more effective
antiplatelet therapy, as the percentage of diabetic patients
was similar among the studies. Finally, although the patient
cohort in the above studies included diabetic patients, there
was no distinction made between diabetic and nondiabetic
patients in terms of in-hospital and late clinical outcomes.
Diabetes and coronary artery stenting. Diabetes remains
an independent risk factor for worse clinical and angio-
graphic outcomes after both balloon angioplasty and stent-
ing in native coronary arteries (1,2,7,8). Analysis from the
Bypass Angioplasty Revascularization Investigation (24)
trial showed worse five-year survival rates in diabetic pa-
tients with multivessel disease treated by balloon angioplasty
compared with those undergoing bypass surgery. In the
study by Stein et al. (2), the five-year survival rate was 89%
in diabetic versus 93% in nondiabetic patients. Likewise,
Kip and colleagues (1) reported a nine-year survival rate of
64% in diabetic and 82% in nondiabetic patients (p ,
0.0001). In another study, Carrozza et al. (7) found in-
creased late loss and greater incidence of restenosis among
diabetic patients after coronary artery stenting as compared
with nondiabetic patients (55% vs. 20%, p 5 0.001).
Although in this study 54% of the lesions were in SVG,
there were a relatively small number of diabetic patients
(n 5 37). In none of the above studies was the effect of
diabetes studied after stent implantation in pure SVG
population.
In this study high procedural success was achieved in both
diabetic and nondiabetic patients. Similarly there was no
difference in the incidence of procedure-related non-Q-
wave MI (creatine kinase isoenzyme $5 times normal
value), distal embolization and subacute stent thrombosis in
both treatment groups. However, in-hospital mortality was
significantly higher in diabetic as compared with nondia-
betic patients. This high prevalence of in-hospital mortality
could be related to the presence of complex SVG lesion
morphology, generalized atherosclerotic disease, reduced
left ventricular function and frequently associated comorbid
conditions in diabetic patients. However, diabetes mellitus
was the sole independent predictor of in-hospital mortality
by multivariate regression analysis.
During follow-up the overall clinical outcome was worse
for diabetic patients due to higher rates of TLR (16.6% vs.
12.3%, p 5 0.001) and increased one-year mortality (12.3%
vs. 5%, p 5 0.001). Consequently, diabetic patients had
lower event-free survival (67% vs. 79%; p 5 0.0003). Several
previous studies have indicated diabetes to be an indepen-
dent predictor of increased late mortality. Elezi et al. (8)
reported a significantly lower event-free survival in diabetic
patients after coronary artery stenting. A Cox proportional
hazard model in that study showed that diabetes correlated
strongly with late mortality. Abizaid et al. (9) in their study
also found diabetes to be independently associated with
higher late mortality after native coronary artery stenting.
Cox proportional hazard regression analysis in our study
also identified diabetes to be an independent predictor of
one-year cumulative mortality. This increased risk was
independent of other comorbid conditions, indicating a
significant influence of diabetes for a worse one-year out-
come in patients undergoing SVG stenting. It is interesting
that prestent atheroablation was an independent predictor
of both TLR and late cardiac events in our study. One
plausible explanation could be that the lesions requiring
atheroablation had more unfavorable baseline lesion char-
acteristics, such as thrombus or degeneration, prompting
the operators to use prestent atheroablation with the hope of
avoiding acute complications. This finding is in contradis-
tinction to a report in native coronary arteries, where
directional atherectomy before stenting resulted in favorable
late outcome (25). These results are not conflicting, how-
ever, as there are inherent differences between the native and
SVG lesions (26). The final reference diameter (average of
the proximal and distal reference segments, which is usually
larger and more accurate for reference vessel size than the
preintervention reference due to underperfusion of the distal
segment before intervention) had a protective effect on late
outcome, suggesting that the larger veins may provide more
room for late neointima or thrombus. The incidence of late
Q-wave MI was similar between diabetic and nondiabetic
patients (2.5% vs. 1.8%, p 5 0.26).
Thus, the findings in this study suggest that, although the
stents appear to equalize the acute angiographic results in
SVG patients regardless of their diabetic status, they do not
eliminate the increased risk of in-hospital mortality and
adverse long-term outcomes that diabetic patients experi-
ence after SVG interventions.
Study limitations. There are several limitations to this
study. First, only the lesions treated with Palmaz-Schatz
stents were included in the analysis. Thus, we cannot
compare different stent designs or evaluate newer stents,
which may have properties better suited for the treatment of
SVG lesions. Second, the relative impact of diabetes mel-
litus on the clinical outcome after SVG stenting was not
studied prospectively, but was rather based on clinical and
angiographic data derived from a large group of consecu-
tively studied patients. The relatively small group of insulin-
requiring diabetic patients analyzed may have resulted in
type II statistical errors when comparing the clinical out-
come to those in noninsulin requiring diabetic group.
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Finally, the follow-up was intentionally truncated at one
year, and long-term follow-up may have produced different
results as vein graft failure continues to develop with time.
Despite these limitations, this study provides clinically
relevant information regarding the detrimental impact of
diabetes mellitus on the acute and late outcomes in patients
undergoing stent implantation in SVG.
Conclusions. In this large series of consecutive patients
undergoing stent implantation in SVG, diabetic patients
compared with nondiabetic patients had: 1) similar in-
hospital procedural success rates, 2) higher in-hospital and
late mortality, 3) higher one year TLR rates, and 4) lower
cardiac event-free survival at one-year follow-up.
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